Guidelines
Comprehensive resource hubs that include guideline summaries and expert insights focused on individual clinical practice guidelines.
Guidelines: Ros1+ NSCLC
An expert highlights the evolution of ROS1-positive non-small cell lung cancer care, emphasizing early RNA-based molecular testing, the 2025 NCCN guideline shift to next-generation TKIs like talotrectinib and repotrectinib, and the need to avoid immunotherapy in favor of personalized, targeted treatment despite challenges in trial access and disease rarity.
